Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The mammalian target of rapamycin (mTOR)/p70 S6 kinase 1 (S6K1) pathway is a critical signaling component in the development of obesity-linked insulin resistance and operates a nutrient-sensing negative feedback loop toward the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt pathway. Whereas acute treatment of insulin target cells with the mTOR complex 1 (mTORC1) inhibitor rapamycin prevents nutrient-induced insulin resistance, the chronic effect of rapamycin on insulin sensitivity and glucose metabolism in vivo remains elusive. RESEARCH DESIGN AND METHODS: To assess the metabolic effects of chronic inhibition of the mTORC1/S6K1 pathway, rats were treated with rapamycin (2 mg/kg/day) or vehicle for 15 days before metabolic phenotyping. RESULTS: Chronic rapamycin treatment reduced adiposity and fat cell number, which was associated with a coordinated downregulation of genes involved in both lipid uptake and output. Rapamycin treatment also promoted insulin resistance, severe glucose intolerance, and increased gluconeogenesis. The latter was associated with elevated expression of hepatic gluconeogenic master genes, PEPCK and G6Pase, and increased expression of the transcriptional coactivator peroxisome proliferator–activated receptor-γ coactivator-1α (PGC-1α) as well as enhanced nuclear recruitment of FoxO1, CRTC2, and CREB. These changes were observed despite normal activation of the insulin receptor substrate/PI 3-kinase/Akt axis in liver of rapamycin-treated rats, as expected from the blockade of the mTORC1/S6K1 negative feedback loop. CONCLUSIONS: These findings unravel a novel mechanism by which mTORC1/S6K1 controls gluconeogenesis through modulation of several key transcriptional factors. The robust induction of the gluconeogenic program in liver of rapamycin-treated rats underlies the development of severe glucose intolerance even in the face of preserved hepatic insulin signaling to Akt and despite a modest reduction in adiposity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Specifically, compensatory pathways are activated in response to chronic rapamycin treatment [66, 67].”
From AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma (2021) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · cited 3×
“Diabetes 59:1338–1348, 2010 The mammalian target of rapamycin (mTOR) is a Ser/Thr kinase that belongs to the phosphatidylinositol (PI) kinase-related protein kinase family (1).”
BackgroundWatterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1
Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C. R., Granner, D. K., et al. (2001) · Nature · doi:10.1038/35093050 · Cited by 1,821 · cited 1×
“We also found that rapamycin markedly increases PGC-1 mRNA expression, which likely contributes to the upregulation of the gluconeogenic enzymes, as observed in type 2 diabetes (32).”
BackgroundAbsence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677
mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex
Cunningham, J. T., Rodgers, J. T., Arlow, D. H., Vazquez, F., Mootha, V. K., & Puigserver, P. (2007) · Nature · doi:10.1038/nature06322 · Cited by 1,488
Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction
Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J., Yoon, J. C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., et al. (2003) · Nature · doi:10.1038/nature01667 · Cited by 1,487
CREB regulates hepatic gluconeogenesis through the coactivator PGC-1
Herzig, S., Long, F., Jhala, U. S., Hedrick, S., Quinn, R., Bauer, A., Rudolph, D., Schutz, G., Yoon, C., Puigserver, P., et al. (2001) · Nature · doi:10.1038/35093131 · Cited by 1,440 · cited 1×
“CREB may also promote gluconeogenesis through increased PGC-1 expression (43).”
BackgroundGuertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,415 · cited 1×
“GSK-3 phosphorylation was recently found to be preserved despite complete loss of Akt Ser473 phosphorylation in mouse embryo fibroblasts from rictor knockout animals (49).”
BackgroundPeterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202 · cited 1×
“The mTOR complex 1 (mTORC1) is composed of mTOR, G L, PRAS40, deptor, and raptor and regulates cell growth, whereas the complex 2 (mTORC2) consists of mTOR, G L, protor-1, mSIN1, deptor, and rictor and controls cytoskeleton regulation and cell survival (1,2).”
Background
Research works printed but not linked: 1
- Hamada, Upregulation of the mTOR complex 1 pathway by Rheb in pancreatic β cells leads to increased β cell mass and prevention of hyperglycemia, Diabetes
Cited by
Items 401–463 of 463
Torres‐Leal, F. L. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2012.tde-20122012-100126 · Cited by 1
Role of Protein Kinase Map4k4 in Energy Metabolism: A Dissertation
Danai, L. V. (2015) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/m2tp40
“Rapamycin, a general mTOR inhibitor, disrupts Srebp-1 expression and maturation, thus decreasing lipogenesis (254, 256, 263-265).”
Effects of immunosuppressive drugs on human adipose tissue metabolism
Pereira, M. J. (2012) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Case Report of Everolimus-Associated DKA in a Patient with Metastatic Renal Cell Carcinoma
Kim, L.-K., Ahn, C. H., Lee, J. E., Jung, C.-H., Koo, B. K., & Moon, M. K. (2014) · Korean Journal of Medicine · doi:10.3904/kjm.2014.86.6.761
“그러나 장기간 ramapycin 치료를 받은 신이식 환자에서 AKT 인산화의 감소, 인슐린 저항성의 증가, 인슐린에 의한 IRS 인산화의 장애가 보고되었고[1,6], 동물 실험에서도 15일간 rapamycin”
InfluentialXenobiotic-metabolizing enzymes elevated in multiple mouse models of slow aging
Steinbaugh, M. J. (2012) · Deep Blue (University of Michigan) · Cited by 1
Regulation of Hepatic Metabolism by the Mechanistic Target of Rapamycin
Lamming, D. W. (2015) · Springer eBooks · doi:10.1007/978-3-319-25065-6_3
Mechanisms of Insulin Resistance after Immunosuppressive Therapy in Brown Adipose Tissue
Ferreira, C. M. D. M. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Sorge, J. (2014) · Human Biology
The Impact Of Folate Restriction On Cancer And Aging: A Mechanistic Analysis
Beydoun, S. (2016) · Human Biology
Schofield, C. J. (2011) · OpenGrey (Institut de l'Information Scientifique et Technique)
Magdalon, J. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2017.tde-19012017-155521
Chronic mTOR Inhibition by Rapamycin and Diabetes
Yan, L., & Cai, Z. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802733-2.00009-8
Paschoal, V. A. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2016.tde-19022016-143923
Avaliação dos preditores de risco cardiovascular no pós-transplante hepático: uma análise de 4 anos
Linhares, L. M. C. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2018.tde-16022018-113230
The Risk Factors of mTORi-Associated Posttransplant Proteinuria
Lim, L., Kung, L., Kuo, M., & Kuo, H. (2018) · Transplantation Proceedings · doi:10.1016/j.transproceed.2018.03.090
mTOR Inhibitors, with Special Focus on Temsirolimus and Similar Agents
Calimeri, T., & Ferreri, A. J. M. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-75184-9_5
Mechanisms Mediating Anti-Inflammatory Effects of Delta-Tocotrienol
Mena, L. T. (2018) · ThinkTech (Texas Tech University)
Andrade, M. L. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2019.tde-18092019-161605
Control Of Systemic Lipid Metabolism By Adipocyte Mtor Signaling
Paolella, L. M. (2020) · Scholarly Commons (University of Pennsylvania)
Jang, S., Kim, B.-R., Jeon, S., Choi, K. S., Lee, E., Lee, J., Lee, E., Han, H., & Cho, J. Y. (2021) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2021.31.1.44
Math and the Fountain of Youth
Sadria, M. (2020) · UWSpace (University of Waterloo)
Minton, D. M. (2020) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
ナタネとレンゲのすき込みが夏ソバの生育・収量に及ぼす影響(日本作物学会四国支部第44回講演会講演要旨)
Sato, Y. S., 杉本, 秀., 池原, 匡., & 亀石, 高. (2007) · 日本作物学会四国支部会報
Tras las huellas de "El segundo sexo" en el pensamiento feminista contemporáneo
Fernández, S. C. (2002) · Dialnet (Universidad de la Rioja) · Cited by 8
Pinto, A. P. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2021.tde-06122021-153922
Current literature in diabetes
(2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1029
Inactivation of mTORC1 Pathway by Aqueous Extract of Acanthopanax senticosus
(2015) · Journal of Integrative Medicine & Therapy · doi:10.13188/2378-1343.1000008
“senticosus stops, depressed mTORC1/S6K activity might be resumed thus not to induce hepatic gluconeogenic shunt as observed in rapamycin, which uncouples between hepatic insulin signaling and glucose homeostasis [18].”
BackgroundVernieri, C., Nichetti, F., Lalli, L., Moscetti, L. I., Giorgi, C. A., Griguolo, G., Marra, A., Randon, G., Rea, C. G., Ligorio, F., et al. (2023) · doi:10.1158/1078-0432.c.6530223
Zhang, X., Hu, Y., & Huang, Y. (2022) · Indian Journal of Dermatology · doi:10.4103/ijd.ijd_560_21 · Cited by 2
Risk Factors and Treatment Progress of Dyslipidemia after Kidney Transplantation
张, 克. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.152460 · Cited by 1
Patricio Astudillo, P. (2025) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2025.04.005
Aladejana, A. E., Sandasi, M., & Viljoen, A. M. (2025) · South African Journal of Botany · doi:10.1016/j.sajb.2025.06.038
Glycoconjugation of Quinoline as an Effective Strategy for Selective Inhibition of mTORC1
Palit, S., Das, T., Majhi, B., Chakrabarti, P., & Dutta, S. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01139
Mandal, S., Brown, A. K., Ekperikpe, U. S., Bhopatkar, A. A., Hughes, K. M., Johnson, T. D., Cooper, J. S., Wilbert, K. T., Cornelius, D. C., & Williams, J. M. (2025) · Experimental Physiology · doi:10.1113/ep092435
Diabète secondaire aux inhibiteurs mTOR
Vergès, B. L. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30071-7
Belforte, N., Agostinone, J., Alarcón-Martínez, L., Villafranca‐Baughman, D., Dotigny, F., Vargas, J. C., & Polo, A. D. (2021) · Figshare · doi:10.6084/m9.figshare.14880590
Zhu, Z., Xu, S., Ren, J., Jiang, T., Zhang, C., & Yan, Z. (2023) · Figshare · doi:10.6084/m9.figshare.24022669
Belforte, N., Agostinone, J., Alarcón-Martínez, L., Villafranca‐Baughman, D., Dotigny, F., Vargas, J. C., & Polo, A. D. (2021) · Figshare · doi:10.6084/m9.figshare.14880593
Sadria, M., & Layton, A. T. (2021) · Figshare · doi:10.6084/m9.figshare.14634182
朱仲玲, Xu, S., Ren, J., Jiang, T., Zhang, C., & Yan, Z. (2023) · Figshare · doi:10.6084/m9.figshare.24022672
Colas, C. (2023) · Corpus Université Laval (Université Laval)
Cellular autophagy and aging: role in intermittent fasting-induced health benefits
Singh, V., Kashif, M., Singh, T., Pahwa, R., Singh, A. K., & Singh, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30060-8.00008-x
Fukae, S., Kakuta, Y., Matsumura, S., Tanaka, Kawamura, M., Nakazawa, S., & Nonomura, N. (2026) · BMC Nephrology · doi:10.1186/s12882-026-04754-y
“EVR modulates the expression of enzymes involved in lipid metabolism, such as lipoprotein lipase, thereby impairing the clearance of plasma lipids by adipose tissue, resulting in hypercholesterolemia [18, 19].”
Uemichi, K., Shirai, T., Shinkai, H., Iwai, R., Iwata, T., Sugiyama, S., & Takemasa, T. (2026) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2025-0316
Li, J., Yang, S., Yuan, Y., Li, N., Wang, X., Wang, Z., Zhu, X., Hua, L., Yu, M., Wang, Y., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103127
mTOR signaling in airway epithelial homeostasis, aging, and diseases
Khatun, Z., Saikat, S., & Haque, S. (2026) · Current Biomedicine · doi:10.29244/currbiomed.4.1.30
“It also impairs tissue repair and causes metabolic disturbances (Houde et al., 2010; Weinreich et al., 2011).”
Wijayasiri, P., Bhat, M., & Aravinthan, A. D. (2026) · Experimental Gerontology · doi:10.1016/j.exger.2026.113105 · Cited by 1
Whitley, S. C., Zhong, R., Baumberger, S., & Richardson, C. E. (2026) · PLoS ONE · doi:10.1371/journal.pone.0345575
Cormerais, Y. (2016) · theses.fr (ABES) · doi:10.70675/94cc6971z3a1dz454fzb65dzf153dc0a3a05 · Cited by 1
Immunothérapie par faibles doses d'IL-2 : potentiel therapeutique dans le diabète de type 1
Pérol, L. (2014) · theses.fr (ABES) · doi:10.70675/ec92b3d1zbfbdz4e97z8339z381d6008e0c8
Obésité et méta-inflammation : rôle du système lysosomal-autophagique et des protéines associées
Soussi, H. (2016) · theses.fr (ABES) · doi:10.70675/77e61e80zde3cz4030z95f1z194698d236d8
Rôle et régulation de l'haptoglobine adipocytaire au cours du vieillissement
Astre, G. (2018) · theses.fr (ABES) · doi:10.70675/91523d31z8a53z44e6z8f1dzf0a02840a7e5
Understanding Aging Genes and Pathways: Insight from Yeast
Taormina, G., & Mirisola, M. G. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48101045
“In addition, chronic rapamycin treatment triggers glucose intolerance and dyslipidemia [201], while its role on testicular atrophy remains more controversial, thereby limiting the use of rapamycin as an anti-aging drug [202,203].”
Lyu, P., Bostancı, A., Jiang, C., Yoo, K. W., Broadhurst, R., Atala, A., & Lu, B. (2026) · Gene Therapy · doi:10.1038/s41434-026-00655-9
Impact of calorie restriction on epigenetic factors and metabolic pathways during senescence
UPASANA, U., PARVEEN, S., & Chakravarty, A. (2015) · FOOD SCIENCE RESEARCH JOURNAL · doi:10.15740/has/fsrj/6.1/148-157
Metadata
- Authors
- Houde, V. P., Brûlé, S., Festuccia, W. T., Blanchard, P.-G., Bellmann, K., Deshaies, Y., & Marette, A.
- Affiliations
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Corresponding author
- Marette, André
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-03-18
- Volume
- 59
- Issue
- 6
- Pages
- 1338-1348
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2874694
- OpenAlex
- W2153442288
- Cited by
- 456
- References
- 51
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 14 · 2023: 25 · 2022: 20 · 2021: 30 · 2020: 25 · 2019: 26 · 2018: 33 · 2017: 37 · 2016: 35 · 2015: 42 · 2014: 47 · 2013: 32 · 2012: 30
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval
- Canadian Institutes of Health Research (144336)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- hepatic gluconeogenesis, impaired glucose tolerance, hyperlipidemia, insulin resistance, PGC-1α, FOXO1, CRTC2, CREB, PI3K/Akt signaling, phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, adiposity
- MeSH terms
- Adipose Tissue, Animals, Blood Glucose, C-Peptide, Fatty Acids, Nonesterified, Glucagon, Hyperlipidemias, Immunosuppressive Agents, Insulin, Liver, Male, Pyruvates, RNA, Triglycerides, Down-Regulation, Polymerase Chain Reaction, Rats, Sprague-Dawley, Adipocytes, Glucose Intolerance, Muscle, Skeletal, Sirolimus, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.